Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

Nature Reviews Drug Discovery

Volumn 8, Issue 10, 2009, Pages 783-793

  Brunden, Kurt R ^a   Trojanowski, John Q ^a   Lee, Virginia M Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ALSTERPAULLONE; AMINOTHIENOPYRIDAZINE; ANILINE; AR A 014418; CHIR 98014; CYCLIN DEPENDENT KINASE 5; DAUNORUBICIN; DOXORUBICIN; EC 102; EXIFONE; GLYCOGEN SYNTHASE KINASE 3; GLYCOSIDASE INHIBITOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HYDRAZIDE DERIVATIVE; METHYLENE BLUE; MICROTUBULE ASSOCIATED PROTEIN 1; N 774; N ACETYL BETA GLUCOSAMINIDASE; OLIGOMER; PACLITAXEL; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE; QUINOXALINE; RAPAMYCIN; RHODANINE; SRN 003 556; TAU PROTEIN; THIAMET G; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; AUTOPHAGY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; LOSS OF FUNCTION MUTATION; MICROTUBULE ASSEMBLY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TAUOPATHY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; DRUG DISCOVERY; HUMANS; TAU PROTEINS; TAUOPATHIES;

EID: 70349638299     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2959     Document Type: Review

References (137)

1. Ballatore, C., Lee, V. M. Y. & Trojanowski, J. Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Rev. Neurosci. 8, 663-672 (2007).
2. Lee, V. M. Y., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Ann. Rev. Neurosci. 24, 1121-1159 (2001).
3. Kidd, M. Paired helical filaments in electron microscopy of alzheimers disease. Nature 197, 192-193 (1963).
4. Arriagada, P. V., Growdon, J. H., Hedleywhyte, E. T. & Hyman, B. T. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimers disease. Neurology 42, 631-639 (1992).
5. Wilcock, G. K. & Esiri, M. M. Plaques, tangles and dementia - a quantitative study. J. Neurological. Sci. 56, 343-356 (1982).
6. GomezIsla, T. et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41 17-24 (1997).
7. George-Hyslop, P. H. & Petit, A. Molecular biology and genetics of Alzheimer's disease. C. R. Biol. 328, 119-130 (2005).
8. Selkoe, D. J. & Schenk, D. Alzheimer's disease: Molecular understanding predicts amyloid-based therapeutics. Ann. Rev. Pharmacol. Toxicol. 43, 545-584 (2003).
9. Goedert, M. Tau gene mutations and their effects. Mov. Disord. 20, S45-S52 (2005).
10. Goedert, M. & Jakes, R. Mutations causing neurodegenerative tauopathies. Biochim. Biophys. Acta 1739, 240-250 (2005).
11. Brandt, R., Hundelt, M. & Shahani, N. Tau alteration and neuronal degeneration in tauopathies: Mechanisms and models. Biochim. Biophys. Acta 1739, 331-354 (2005).
12. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 353-356 (2002).
13. Drechsel, D. N., Hyman, A. A., Cobb, M. H. & Kirschner, M. W. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell 3, 1141-1154 (1992).
14. Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E. M. & Mandelkow, E. Domains of tau-protein and interactions with microtubules. Biochemistry 33, 9511-9522 (1994).
15. Binder, L. I., Frankfurter, A. & Rebhun, L. I. The distribution of tau in the mammalian central nervous system. J. Cell Biol. 101, 1371-1378 (1985).
16. Andreadis, A., Brown, W. M. & Kosik, K. S. Structure and novel exons of the human-tau gene. Biochemistry 31, 10626-10633 (1992).
17. Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D. & Crowther, R. A. Multiple isoforms of human microtubule-associated protein-tau - sequences and localization in neurofibrillary tangles of Alzheimers disease. Neuron 3, 519-526 (1989).
18. Panda, D., Samuel, J. C., Massie, M., Feinstein, S. C. & Wilson, L. Differential regulation of microtubule dynamics by three- and four-repeat tau: Implications for the onset of neurodegenerative disease. Proc. Natl Acad. Sci. USA 100, 9548-9553 (2003).
19. Spillantini, M. G. et al. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments. Proc. Natl Acad. Sci. USA 94, 4113-4118 (1997).
20. Dayanandan, R. et al. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation. FEBS Lett. 446, 228-232 (1999).
21. Hasegawa, M., Smith, M. J. & Goedert, M. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 437, 207-210 (1998).
22. Hong, M. et al. Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17. Science 282, 1914-1917 (1998).
23. Barghorn, S. et al. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry 39, 11714-11721 (2000).
24. Gamblin, T. C. et al. In vitro polymerization of tau protein monitored by laser light scattering: Method and application to the study of FTDP-17 mutants. Biochemistry 39, 6136-6144 (2000).
25. Nacharaju, P. et al. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. J. Neuropathol. Exp. Neurol. 58, 545 (1999).
26. Avila, J., Santa-Maria, I., Perez, M., Hernandez, F. & Moreno, F. Tau phosphorylation, aggregation, and cell toxicity. J. Biomed. Biotechnol. 2006, 74539 (2006).
27. Avila, J. Tau and tauopathies: Tau phosphorylation and tau assembly. FEBS J. 273, 23 (2006).
28. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. & Hof, P. R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33, 95-130 (2000).
29. Merrick, S. E., Trojanowski, J. Q. & Lee, V. M. Y. Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons (NT2N cells). J. Neurosci. 17, 5726-5737 (1997).
30. Wagner, U., Utton, M., Gallo, J. M. & Miller, C. C. J. Cellular phosphorylation of tau by GSK-3β influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 109, 1537-1543 (1996).
31. Alonso, A. D., GrundkeIqbal, I. & Iqbal, K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nature Med. 2, 783-787 (1996).
32. Alonso, A. D., GrundkeIqbal, I. & Iqbal, K. Abnormally phosphorylated tau from Alzheimer disease brain depolymerizes microtubules. Neurobiol. Aging 15, S37 (1994).
33. Necula, M. & Kuret, J. Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro. J. Biol. Chem. 279, 49694-49703 (2004).
34. Kins, S. et al. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem. 276, 38193-38200 (2001).
35. Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W. & Gong, C. X. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 10804-10809 (2004).
36. Lefebvre, T. et al. Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins - a role in nuclear localization. Biochim. Biophys. Acta 1619, 167-176 (2003).
37. Lee, G. et al. Phosphorylation of tau by fyn: Implications for Alzheimer's disease. J. Neurosci. 24, 2304-2312 (2004).
38. Gong, C. X., Liu, F., Grundke-Iqbal, I. & Iqbal, K. Post-translational modifications of tau protein in Alzheimer's disease. J. Neural Transm. 112, 813-838 (2005).
39. Park, S. Y. & Ferreira, A. The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates β-amyloid-induced neurodegeneration. J. Neurosci. 25, 5365-5375 (2005).
40. Gamblin, T. C. et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl Acad. Sci. USA 100, 10032-10037 (2003).
41. Chirita, C. N., Necula, M. & Kuret, J. Anionic micelles and vesicles induce tau fibrillization in vitro. J. Biol. Chem. 278, 25644-25650 (2003).
42. Wilson, D. M. & Binder, L. I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease. Am. J. Pathol. 150, 2181-2195 (1997).
43. Gauthier, S. et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: Exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging 13, 550-557 (2009).
44. Green, R. C., Schneider, L. S., Hendrix, S., Zavitz, K. & Swabb, E. Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18 month multicenter phase 3 trial. Eur. J. Neurol. 15, 412 (2008).
45. Hempen, B. & Brion, J. P. Reduction of acetylated α-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 55, 964-972 (1996).
46. Bendiske, J., Caba, E., Brown, Q. B. & Bahr, B. A. Intracellular deposition, microtubule destabilization, and transport failure: An "early" pathogenic cascade leading to synaptic decline. J. Neuropathol. Exp. Neurol. 61, 640-650 (2002).
47. Ishihara, T. et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24, 751-762 (1999).
48. Cash, A. D. et al. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am. J. Pathol. 162, 1623-1627 (2003).
49. Yuan, A., Kumar, A., Peterhoff, C., Duff, K. & Nixon, R. A. Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 28, 1682-1687 (2008).
50. Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007).
51. Harada, A. et al. Altered microtubule organization in small-caliber axons of mice lacking tau protein. Nature 369, 488-491 (1994).
52. Dawson, H. N. et al. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J. Cell Sci. 114 1179-1187 (2001).
53. Ikegami, S., Harada, A. & Hirokawa, N. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci. Lett. 279, 129-132 (2000).
54. Zhang, B. et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc. Natl Acad. Sci. USA 102, 227-231 (2005).
55. Gozes, I. & Divinski, I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J. Alzheimers Dis. 6, S37-S41 (2004).
56. Matsuoka, Y. et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J. Mol. Neurosci. 31, 165-170 (2007).
57. Matsuoka, Y. et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J. Pharmacol. Exp. Ther. 325, 146-153 (2008).
58. Ballatore, C. et al. Paclitaxel C-10 carbamates: Potential candidates for the treatment of neurodegenerative tauopathies. Bioorg. Med. Chem. Lett. 17, 3642-3646 (2007).
59. Fellner, S. et al. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J. Clin. Invest. 110, 1309-1318 (2002).
60. Matsuo, E. S. et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimers disease paired helical filament tau. Neuron 13, 989-1002 (1994).
61. Hasegawa, M. et al. Protein sequence and mass spectrometric analyses of tau in the Alzheimers disease brain. J. Biol. Chem. 267, 17047-17054 (1992).
62. Hanger, D. P., Anderton, B. H. & Noble, W. Tau phos phory lation: The therapeutic challenge for neuro degenerative disease. Trends Mol. Med. 15, 112-119 (2009).
63. Sengupta, A. et al. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch. Biochem. Biophys. 357, 299-309 (1998).
64. Alonso, A. D., Mederlyova, A., Novak, M., Grundke-Iqbal, I. & Iqbal, K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J. Biol. Chem. 279, 34873-34881 (2004).
65. Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E. & Mandelkow, E. M. Phosphorylation that detaches tau from microtubules S262 and S214 protects it against aggregation into Alzheimer paired helical filaments. J. Neurochem. 73, S26 (1999).
66. Ghoreschi, K., Laurence, A. & O'Shea, J. J. Selectivity and therapeutic inhibition of kinases: To be or not to be? Nature Immunol. 10 356-360 (2009).
67. Mazanetz, M. P. & Fischer, P. M. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nature Rev. Drug Discov. 6, 464-479 (2007).
68. Gong, C. X. & Iqbal, K. Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease. Curr. Med. Chem. 15, 2321-2328 (2008).
69. Imahori, K. & Uchida, T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem. 121, 179-188 (1997).
70. Pei, J. J. et al. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56, 70-78 (1997).
71. Lucas, J. J. et al. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mice. EMBO J. 20, 27-39 (2001).
72. Hernandez, F., Borrell, J., Guaza, C., Avila, J. & Lucas, J. J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3β in the brain but do not form tau filaments. J. Neurochem. 83, 1529-1533 (2002).
73. Lee, K. Y. et al. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34, 21-29 (1999).
74. Tseng, H. C., Zhou, Y., Shen, Y. & Tsai, L. H. A survey of Cdk5 activator p35 and p25 levels in Alzheimer's disease brains. FEBS Lett. 523, 58-62 (2002).
75. Yamaguchi, H. et al. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK)I glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 92, 232-241 (1996).
76. Augustinack, J. C., Sanders, J. L., Tsai, L. H. & Hyman, B. T. Colocalization and fluorescence resonance energy transfer between cdk5 and AT8 suggests a close association in pre-neurofibrillary tangles and neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 61, 557-564 (2002).
77. Pei, J. J. et al. Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797, 267-277 (1998).
78. Noble, W. et al. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565 (2003).
79. Cruz, J. C. et al. P25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid β in vivo. J. Neurosci. 26, 10536-10541 (2006).
80. Phiel, C. J., Wilson, C. A., Lee, V. M. Y. & Klein, P. S. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435-439 (2003).
81. Aplin, A. E., Jacobsen, J. S., Anderton, B. H. & Gallo, J. M. Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Neuroreport 8 639-643 (1997).
82. Rockenstein, E. et al. Neuroprotective effects of regulators of the glycogen synthase kinase-3β signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27, 1981-1991 (2007).
83. Wen, Y. et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci. 28, 2624-2632 (2008).
84. Drewes, G., Ebneth, A., Preuss, U., Mandelkow, E. M. & Mandelkow, E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89, 297-308 (1997).
85. Chin, J. Y. et al. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: A fluorescence resonance energy transfer study. J. Neuropathol. Exp. Neurol. 59, 966-971 (2000).
86. Nishimura, I., Yang, Y. F. & Lu, B. W. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116, 671-682 (2004).
87. Medina, M. & Castro, A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Dev. 11, 533-543 (2008).
88. Dhavan, R. & Tsai, L. H. A decade of CDK5. Nature Rev. Mol. Cell Biol. 2, 749-759 (2001).
89. Biernat, J. et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol. Cell 13, 4013-4028 (2002).
90. Mandelkow, E. M., Thies, E., Trinczek, B., Biernat, J. & Mandelkow, E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J. Cell Biol. 167, 99-110 (2004).
91. Churcher, I. Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr. Top. Med. Chem. 6, 579-595 (2006).
92. Lee, V. M. Y., Kenyon, T. K. & Trojanowski, J. Q. Transgenic animal models of tauopathies. Biochim. Biophys. Acta 1739, 251-259 (2005).
93. Noble, W. et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl Acad. Sci. USA 102, 6990-6995 (2005).
94. Perez, M., Hernandez, F., Lim, F., Diaz-Nido, J. & Avila, J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 5, 301-308 (2003).
95. Nakashima, H. et al. Effect of chronic lithium treatment on an animal model of tauopathies. Neurobiol. Aging 25, S595 (2004).
96. Engel, T., Goni-Oliver, P., Lucas, J. J., Avila, J. & Hernandez, F. Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J. Neurochem. 99, 1445-1455 (2006).
97. Caccamo, A., Oddo, S., Tran, L. X. & LaFerla, F. M. Lithium reduces tau phosphorylation but not Aβ or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170, 1669-1675 (2007).
98. Hampel, H. et al. Lithium trial in Alzheimer's disease: A randomized, single-blind, placebo-controlled multicenter 10-week study. J. Clin. Psychiatry 70, 922-931 (2009).
99. Le Corre, S. et al. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl Acad. Sci. USA 103, 9673-9678 (2006).
100. Selenica, M. L. et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Brit. J. Pharmacol. 152, 959-979 (2007).
101. Fischer, P. M. Turning down tau phosphorylation. Nature Chem. Biol. 4, 448-449 (2008).
102. Yuzwa, S. A. et al. A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nature Chem. Biol. 4, 483-490 (2008).
103. Hasegawa, M., Crowther, R. A., Jakes, B. & Goedert, M. Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J. Biol. Chem. 272, 33118-33124 (1997).
104. Wischik, C. M., Edwards, P. C., Lai, R. Y. K., Roth, M. & Harrington, C. R. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA 93, 11213-11218 (1996).
105. Staff, R. T. et al. Tau aggregation inhibitor (TAI) therapy with rember arrests the trajectory of rCBF decline in brain regions affected by tau pathology in mild to moderate Alzheimer's disease. Alzheimers Dement. 4, T775 (2008).
106. Chirita, C., Necula, M. & Kuret, J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43, 2879-2887 (2004).
107. Congdon, E. E., Necula, M., Blackstone, R. D. & Kuret, J. Potency of a tar fibrillization inhibitor is influenced by its aggregation state. Arch. Biochem. Biophys. 465, 127-135 (2007).
108. Pickhardt, M. et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J. Biol. Chem. 280, 3628-3635 (2005).
109. Khlistunova, I. et al. Inducible expression of tau repeat domain in cell models of tauopathy: Aggregation is toxic to cells but can be reversed by inhibitor drugs. J. Biol. Chem. 281, 1205-1214 (2006).
110. Larbig, G., Pickhardt, M., Lloyd, D. G., Schmidt, B. & Mandelkow, E. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: A ligand based approach results in successful scaffold hopping. Curr. Alzheimer Res. 4, 315-323 (2007).
111. Pickhardt, M. et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46, 10016-10023 (2007).
112. Bulic, B. et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed. Engl. 46, 9215-9219 (2007).
113. Taniguchi, S. et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J. Biol. Chem. 280, 7614-7623 (2005).
114. Crowe, A., Ballatore, C., Hyde, E., Trojanowski, J. Q. & Lee, V. M. Y. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem. Biophys. Res. Commun. 358, 1-6 (2007).
115. Crowe, A. et al. The identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48, 7732-7745 (2009).
116. Feng, B. Y. et al. Small-molecule aggregates inhibit amyloid polymerization. Nature Chem. Biol. 4, 197-199 (2008).
117. Congdon, E. E. et al. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J. Biol. Chem. 283, 13806-13816 (2008).
118. Drubin, D. G., Feinsteni, S. C., Shooter, E. M. & Kirschner, M. W. Nerve growth factor-induced neurite outgrowth in PC12 cells involves the coordinate induction of microtubule assembly and assemblypromoting factors. J. Cell Biol. 101, 1799-1807 (1985).
119. Brunden, K., Trojanowski, J. Q. & Lee, V. M. Y. Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J. Alzheimers Dis. 14, 393-399 (2008).
120. Ravikumar, B., Sarkar, S., Berger, Z. & Rubinsztein, D. C. The roles of the ubiquitin-proteasome and autophagy-lysosome pathways in Huntington's disease and related conditions. Clin. Neurosci. Res. 3, 141-148 (2003).
121. Nixon, R. A. Autophagy in neurodegenerative disease: Friend, foe or turncoat? Trends Neurosci. 29, 528-535 (2006).
122. Nixon, R. A. et al. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 64, 113-122 (2005).
123. Hamos, J. E. et al. Expression of heat-shock proteins in Alzheimers disease. Neurology 41, 345-350 (1991).
124. Perez, N. et al. Increased synthesis and accumulation of heat-shock 70 proteins in Alzheimers disease. Mol. Brain Res. 11, 249-254 (1991).
125. Keck, S., Nitsch, R., Grune, T. & Ullrich, O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J. Neurochem. 85, 115-122 (2003).
126. Keller, J. N., Hanni, K. B. & Markesbery, W. R. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75, 436-439 (2000).
127. Dickey, C. A. et al. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117, 648-658 (2007).
128. Zhang, H. & Burrows, F. Targeting multiple signal transduction pathways through inhibition of HSP90. J. Mol. Med. 82, 488-499 (2004).
129. Dickey, C. A. et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. Faseb J. 20, 753-755 (2006).
130. Luo, W. J. et al. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl Acad. Sci. USA 104, 9511-9516 (2007).
131. Kamal, A. et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425, 407-410 (2003).
132. Williams, A. et al. Aggregate-prone proteins are cleared from the cytosol by autophagy: Therapeutic implications. Curr. Top. Dev. Biol. 76, 89-101 (2006).
133. Berger, Z. et al. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15, 433-442 (2006).
134. Hamano, T. et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur. J. Neurosci. 27, 1119-1130 (2008).
135. Sarkar, S. et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170, 1101-1111 (2005).
136. SantaCruz, K. et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481 (2005).
137. Friedhoff, P., Schneider, A., Mandelkow, E. M. & Mandelkow, E. Rapid assembly of Alzheimer-like paired helical filaments from microtubule-associated protein tau monitored by fluorescence in solution. Biochemistry 37, 10223-10230 (1998).